We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 639

Pharmaceutical Compound Nonobvious Absent Evidence Suggesting Specific Modification to Prior Art Compound
  • Jones Day
  • USA
  • April 20 2017

The PTAB issued a Final Written Decision in IPR2016-00204, upholding the validity of claims 1-13 of Patent RE38,551 E (“the ’551 patent”), which


Food, Dietary Supplement & Cosmetics Update Vol. IV, Issue 3
  • Jones Day
  • European Union, USA
  • April 13 2017

On April 6, 2017, the Food and Drug Administration ("FDA") notified industry regarding the amendment of waivers available under the Sanitary


Pharmaceutical & Medical Device Regulatory Update, Vol. IV, Issue 1
  • Jones Day
  • USA
  • April 12 2017

One day before the final rule, "Clarification of When Products Made or Derived From Tobacco Are Regulated as Drugs, Devices, or Combination Products


Second Circuit Affirms Dismissal of False Claims Act Medicare Secondary Payer Cases
  • Jones Day
  • USA
  • April 7 2017

The Second Circuit affirmed the dismissal of two False Claims Act ("FCA") cases brought by private relators against insurance and other companies


PTAB Invalidates Two Anacor KERYDIN Patents
  • Jones Day
  • USA
  • March 30 2017

The PTAB found obvious all claims of U.S. Patent Nos. 7,582,621 and 7,767,657 in the three final written decisions issued on February 23, 2017


Including Functional Claim Language Helped Save Pozen’s VIMOVO Patents
  • Jones Day
  • USA
  • March 21 2017

On February 28, 2017, the PTAB held that the petitioner Lupin had not shown that the challenged claims in two of Pozen’s patents were invalid


Food, Dietary Supplement & Cosmetics Regulatory Update Vol. IV, Issue 2
  • Jones Day
  • European Union, USA
  • March 17 2017

President Trump to Nominate Scott Gottlieb as FDA Commissioner According to a White House statement, President Trump


Global Privacy & Cybersecurity Update Vol. 13 - March 2017
  • Jones Day
  • Asia-Pacific, Australia, Canada, Central & South America, China, European Union, Hong Kong, Japan, Singapore, USA
  • March 10 2017

On December 28, 2016, the New York Department of Financial Services ("DFS") released a revised version of a proposed regulation that would require


Secondary Considerations Unsuccessful Once Again
  • Jones Day
  • USA
  • March 1 2017

As reported in our February 1, 2017 post, patent owners have had a difficult time convincing the PTAB that secondary considerations are sufficient to


PTAB Rejects Flawed Inherency Argument Against Drug Composition Patent
  • Jones Day
  • USA
  • February 24 2017

On February 3, 2017, the PTAB denied a petition by Amneal Pharmaceuticals LLC ("Amneal") to institute an inter partes review of Hospira Inc.'s patent